Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China
Pharmacoeconomics and Policy · 2026-03 · 2 (1) · 46-53
DOI: 10.1016/j.pharp.2026.03.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoeconomics and Policy, 2026-03. Verfasst von Kaijie Yao und 6 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Yao, K., Bao, Y., Chen, Y., Zhong, Y., Yan, M., Li, W., & Wu, B. (2026). Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China. Pharmacoeconomics and Policy, 2(1), 46-53. https://doi.org/10.1016/j.pharp.2026.03.006
Vancouver
Yao K, Bao Y, Chen Y, Zhong Y, Yan M, Li W, et al. Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China. Pharmacoeconomics and Policy. 2026;2(1):46-53. doi:10.1016/j.pharp.2026.03.006
BibTeX
@article{Yao2026,
author = {Yao, Kaijie and Bao, Yun and Chen, Ying and Zhong, Yan and Yan, Mengxia and Li, Wen and Wu, Bin},
title = {Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China},
journal = {Pharmacoeconomics and Policy},
year = {2026},
volume = {2},
number = {1},
pages = {46--53},
doi = {10.1016/j.pharp.2026.03.006}
}
EUVIMED